A new Northwestern Medicine study published in JAMA reveals that measuring apolipoprotein B (apoB) outperforms traditional cholesterol tests in guiding statin therapy, potentially preventing more heart attacks and strokes cost-effectively for U.S. healthcare payers.
For years, clinicians have relied on standard lipid panels measuring low-density lipoprotein (LDL), often called bad cholesterol, and non-HDL cholesterol to make decisions about statins and other medications. But routine blood tests taken by millions of Americans each year may not provide the full picture needed to prevent cardiovascular events, according to researchers at Northwestern University Feinberg School of Medicine.
Why Apolipoprotein B Outperforms Traditional Cholesterol Panels
The core limitation of standard cholesterol tests is that they fail to count the actual number of harmful particles circulating in the bloodstream. When small, cholesterol-carrying particles get struck in arteries, they form plaques over time, ultimately causing the blockages that lead to heart attacks and strokes. Apolipoprotein B testing provides a clearer metric because it counts the total number of harmful particles in the blood.
Despite this clinical advantage, apoB is not widely used in routine care. The test typically requires an additional blood test besides the standard cholesterol panel, introducing hurdles related to cost and convenience.
Computer Simulation Model Proves Cost-Effectiveness
To determine whether the added expense of apoB testing is justified, Northwestern scientists constructed a computer simulation model representing 250,000 U.S. adults who were eligible for statins but without existing cardiovascular disease.
- LDL cholesterol targeted at a goal below 100 mg/dL
- Non-HDL cholesterol targeted at a goal below 118 mg/dL
- ApoB targeted at a goal below 78.7 mg/dL
Under each strategy, if patients did not meet their assigned goal, treatment was first intensified with stronger statins, followed by the addition of ezetimibe. The analysis tracked clinical outcomes including heart attacks, strokes, life expectancy, quality of life, and healthcare costs. The simulation demonstrated that apoB-guided care outperformed both traditional strategies by improving population health and saving more lives in a cost-effective manner.
“We found that apoB testing to intensify cholesterol-lowering medication would prevent more heart attacks and strokes than current practice, and that these health benefits were achieved at a cost that represents good value for U.S. healthcare payers,”
Ciaran Kohli-Lynch, assistant professor of preventive medicine in the division of epidemiology at Northwestern University Feinberg School of Medicine
New Heart Guidelines Raise the Stakes for Precise Risk Assessment
The timing of the new findings aligns with shifting clinical standards. Over the past decade, the number of medications available to doctors to lower cholesterol has vastly expanded. Furthermore, the American Heart Association and 10 other medical associations issued new guidelines earlier this year recommending the initiation of cholesterol-lowering therapy at younger ages for many patients.
This policy shift makes accurate risk stratification more critical. As preventive care reaches younger cohorts, identifying which patients would benefit most from intensive treatment becomes essential.
Broader Cardiovascular Screening Raises Questions About CAC Testing Value
While blood biomarkers like apoB look at particle counts, other diagnostic tools face renewed scrutiny regarding their clinical utility. Recent research suggests that coronary artery calcium (CAC) testing — an increasingly popular test that checks for plaque in the arteries feeding the heart — may not provide much value for many people, despite heart disease remaining the number-one killer of both men and women in the United States.
Conversely, separate data from Intermountain Health researchers presenting at American Heart Association Scientific Sessions 2025 in New Orleans indicates that CAC scores hold unexpected prognostic value beyond cardiovascular disease. Analyzing medical records of 40,018 patients over a five-year follow-up period, investigators found that people who had any level of coronary artery calcium were 2 to 3 times more likely to have died than those without CAC.
Interestingly, of those with CAC who died, only about one quarter did so from cardiovascular disease, suggesting that coronary plaque may be correlated with plaque in blood vessels in other parts of the body, and having atherosclerosis may also negatively impact immune surveillance, an important protective mechanism against cancer.
